Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEGA-OA4C174
- Development stage
- Preclinical
- Lead developer
- University of California, Davis
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PEGA-OA4C174 is a pan-affinitive telodendrimer nanotrap (TDNT) resin designed for the extracorporeal removal of inflammatory cytokines in patients with sepsis. Developed by researchers at the University of California, Davis, this hemoperfusion resin consists of macroporous polyethylene glycol acrylamide (PEGA) beads functionalized with highly branched telodendrimers. These telodendrimers are engineered to capture a broad range of cytokines through a combination of charge-based and hydrophobic interactions, effectively neutralizing the "cytokine storm" associated with systemic inflammation. Compared to traditional macroporous resins, PEGA-OA4C174 exhibits high cytokine clearance efficiency with significantly reduced non-specific adsorption of essential serum proteins, suggesting superior biocompatibility and a lower risk of adverse effects during blood purification.
- Other names
- pan-affinitive TDNT resintelodendrimer nanotrap resin
02
Targets
IL-6 (Interleukin 6)IL10 (Interleukin-10)IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))IL8 (C-X-C Motif Chemokine Ligand 8)
Beyond the preview
Go deeper on PEGA-OA4C174.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEGA-OA4C174.